

22 March, 2018

Dear Dr Wang,

**Manuscript Number: 38308**

**Title: RISK OF GASTRIC CANCER DEVELOPMENT AFTER ERADICATION OF  
HELICOBACTER PYLORI**

Thank you for your letter concerning the revision of our manuscript. The followings are the responses to the reviewers' comments.

We hope that the reviewers and editors will find this revised version acceptable for publication in the World Journal of Gastrointestinal Oncology.

Yours sincerely,

Wai K. Leung

## **Editor's comments**

Concerning the language of the manuscript, we have asked for advice from our colleague who is a native English speaker.

## **Reviewers' Comments to Author**

### **Reviewer no: 02573214**

The work does not present any kind of originality, but it is a concise and comprehensive good description of the state of art about the risk of gastric cancer development after eradication of *Helicobacter Pylori*.

We thank you for your comments. Our article actually addressed the risk factors for gastric cancer after eradication of *Helicobacter pylori* (*H. pylori*), especially the potential effects of various drugs which has not adequately explored by current literature. This is because the majority of previous studies included both *H.pylori*-infected and negative subjects, leading to the inconclusive conclusion of gastric cancer risk with various medications.

As an example, our articles on the influences of proton pump inhibitors and aspirin on the gastric cancer risk after *H. pylori* eradication have only been recently published in Gut and Journal of National Cancer Institute, respectively. Our review indeed is a very up-to-date one. We also proposed further research perspectives in our review concerning the potential role of statins and metformin.

### **Reviewer no: 02683307**

This is well written ms.

We thank you for your comments.